US FDA rule change could prompt rethink of pharma IP strategy
Employee mobility and growing collaboration have already elevated the strategic importance of trade secrets and process patents across the life sciences industry. A new US Food and Drug Administration proposal aimed...To view the full article, register now.
Already a subscriber? Click here to view full article